Evaluation of Serum Levels of HER2, MMP-9, Nitric Oxide, and Total Antioxidant Capacity in Egyptian Breast Cancer Patients: Correlation with Clinico-Pathological Parameters

Yara A. RASHAD ¹, Tawfik R. ELKHODARY ², Amal M. EL-GAYAR ¹, Laila A. EISSA * ¹

¹ Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.
² Oncology Center, Mansoura University, Mansoura, 35516, Egypt.

* Corresponding author. E-mail: lailaeissa2002@yahoo.com or yaraadel1290@yahoo.com (L. A. Eissa)

Abstract

Breast cancer is by far the most common cancer in women worldwide and the main cause of cancer-related mortality. Breast cancer accounts for 38% of all malignancies among Egyptian women. The aim of our study was to evaluate the serum levels of human epidermal growth factor receptor-2 (HER2), matrix metalloproteinase-9 (MMP-9), nitric oxide (NO), and total antioxidant capacity (TAC) in breast cancer patients and to correlate these markers with clinico-pathological parameters. Serum HER2, MMP-9, and carcinoma antigen 15-3 (CA 15-3) were assessed in 80 breast cancer patients and ten healthy subjects as a control group by the enzyme-linked immunosorbert assay (ELISA) technique while NO and TAC were assessed by a colorimetric method. Serum HER2 was ≥15 ng/mL in nine patients (11.3%). High HER2 ECD levels were significantly associated with tissue HER2 (P<0.0001), metastasis (P= 0.0024), and negativity of both estrogen (P=0.0075) and progesterone (P=0.0239) receptors. Serum MMP-9 (P=0.0013), NO (P<0.0001), and CA 15-3 (P<0.0001) were significantly increased while serum TAC was significantly (P=0.01) decreased in breast cancer patients as compared to the control group. Serum MMP-9 was increased significantly (P=0.028) in metastatic patients as compared to non-metastatic patients. We found a positive correlation between serum HER2 and CA 15-3 (r=36, p=0.005). In conclusion, serum HER2 reflects the tissue HER2 status of breast cancer, so the determination of serum HER2 is...
helpful in assessing HER2 status, but in addition, a high level may reflect metastatic disease. Also, serum MMP-9 can be useful for denoting the development of metastasis in breast cancer patients. Follow-up is needed to evaluate the value of serum HER2 and MMP-9 as prognostic markers.

Keywords
Human epidermal growth factor receptor-2 (HER2) • Matrix metalloproteinase-9 (MMP-9) • Nitric oxide (NO) • Total antioxidant capacity (TAC) • Carcinoma Antigen 15-3 (CA15-3) • Breast cancer

Introduction
Breast cancer is by far the most common cancer in women worldwide and the main cause of cancer-related mortality [1]. In Egypt, as in many other parts of the world, breast cancer is the most common type of cancer: it accounts for approximately 38% of reported malignancies among Egyptian women [2].

The human epidermal growth factor receptor (HER)-2 (HER2/neu, c-erbB-2) is a transmembrane receptor that is overexpressed in 15–25% of breast cancers. HER2 overactivity is associated with adverse biological characteristics and poor clinical outcomes. Therefore, it is an attractive target for therapeutic intervention, a strategy that has been clinically validated [3]. HER2 is a member of the HER family of transmembrane receptors, which are characterized by the presence of an extracellular ligand-binding domain, an intracellular tyrosine kinase domain, and a cytoplasmic tail. HER2 can release its ECD through a proteolytic mechanism, known as ECD shedding [4]. Currently, tissue HER2/neu status has mainly been evaluated using immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) (when IHC results are equivocal) in the clinical setting [5]. The serum extracellular domain fragment of HER2 (HER2 ECD) represents a non-invasive and quantifiable biomarker that could supplement existing HER2/neu testing [6].

MMPs in humans are a family of 23 members that have been associated with remodeling of the extracellular matrix (ECM). Because of their involvement in the processing of ECM, MMPs were implicated in cancer invasion and metastasis [7]. HER2 shedding has been attributed to various zinc-containing metalloproteases including members of the ADAM (A Disintegrin And Metalloproteases) and MMP families [8]. On the basis of the detection of high activity of proMMP-9 in the sera and tissues of breast cancer patients, it is proposed that tissue MMPs may appear in the bloodstream in increased amounts in patients with biologically aggressive breast cancer, thereby providing a unique marker that might be useful for predicting the appearance of metastasis [9].

NO is a ubiquitous, water-soluble, free radical gas, which plays a key role in various physiological as well as pathological processes. It is synthesized by a complex family of nitric oxide synthase (NOS) enzymes [10]. Numerous clinical and experimental studies have implicated that NO and its derivatives have a critical impact on various carcinomas including breast cancer [11].
In order to develop an effective strategy to prevent and treat certain disorders, an accurate evaluation of ROS and antioxidants has a critical importance. The understanding of causes and progression of breast cancer contributes to the development of diagnosis and treatment. In addition to the parameters which are being used for following up cancer prevention, cancer diagnosis, and treatment, TAC level can also be used [12]. The major advantage of measuring TAC is to measure the antioxidant capacity of all antioxidants in a biological sample and not just the antioxidant capacity of a single compound.

Results and Discussion

We measured serum HER2, MMP-9, NO, and TAC levels in patients with breast cancer and healthy controls and evaluated the value of these markers. The main tumor characteristics are summarized in Table 1. T1, T2 tumor size were reported in 48 patients (60%) and T3, T4 were reported in 32 patients (40%). Lymph node negative was reported in 15 patients (18.75%) and lymph node positive was reported in 55 patients (68.8%). Grade II was reported in 68 patients (85%) and grade III was reported in 12 patients (15%). Metastasis was present in 41 patients (51.25%) and absent in 39 patients (48.75%).

| Breast cancer patients | N (%) |
|------------------------|-------|
| Tumor Size             |       |
| T1                     | 6 (7.5%) |
| T2                     | 42 (52.5%) |
| T3                     | 16 (20%) |
| T4                     | 16 (20%) |
| Tumor Grade            |       |
| G II                   | 68 (85%) |
| G III                  | 12 (15%) |
| LN stage               |       |
| N0                     | 15 (18.75%) |
| N1                     | 20 (25.0%) |
| N2                     | 16 (20.0%) |
| N3                     | 19 (23.8%) |
| Unknown                | 10 (12.5%) |
| Metastasis             |       |
| Absent                 | 39 (48.75%) |
| Present                | 41 (51.25%) |
| Tumor stage            |       |
| I                      | 1 (1.25%) |
| II                     | 15 (18.75%) |
| III                    | 23 (28.75%) |
| IV                     | 41 (51.25%) |

N: number of patients; LN: lymph node.

Receptor statuses of the patients are summarized in Table 2. Cancer tissue HER2 status was positive (3+ by immunohistochemistry [IHC] or 2+ by IHC with FISH amplification) in 20 patients (25.0%) and negative in 60 patients (75.0%).
Tab. 2.  Receptor status of the patients in our series

|                          | Breast cancer patients |
|--------------------------|------------------------|
|                          | N (%)                  |
| ER-ve                    | 28 (35%)               |
| ER+ve                    | 52 (65%)               |
| PgR-ve                   | 31 (38.8%)             |
| PgR+ve                   | 49 (61.2%)             |
| Tissue HER2-ve           | 60 (75.0%)             |
| Tissue HER2+ve           | 20 (25.0%)             |
| ER/HER2                  |                        |
| ER +ve/HER2 -ve          | 42 (52.5%)             |
| ER +ve/HER2 +ve          | 10 (12.5%)             |
| ER-ve/HER2+ve            | 10 (12.5%)             |
| PgR+ve/ER+ve/HER2-ve     | 37 (46.25%)            |
| PgR+ve/ER-ve/HER2-ve     | 2 (2.5%)               |
| Triple negative          | 16 (20%)               |

N: number of patients; ER: estrogen receptor; PgR: progesterone receptor; HER2: human epidermal growth factor receptor-2.

Tumor therapy and surgical procedures of the breast cancer patients are summarized in Table 3. Breast conservative surgery was carried out in 2 patients (2.5%) and modified radical mastectomy in 67 patients (83.8%). Radiotherapy was delivered to 40 patients (50%). Chemotherapy was administered to 75 patients (93.6%). Hormonal therapy was administered to 43 patients (53.7%). In spite of trastuzumab approval for the treatment of HER2-positive patients, none of our patients in this study at that time received trastuzumab because of its high cost, but nowadays our policy is to administer trastuzumab to HER2-positive patients.

Fig. 1.  Association between tissue HER2 status and serum HER2 ECD levels.
**Serum HER2 ECD:**
With a cut-off value of 15 ng/mL, 9 out of the 80 patients (11.3%) had HER2 ECD levels ≥15 ng/mL (high levels) and 71 out of the 80 patients (88.7%) had HER2 ECD levels <15 ng/mL (low levels).

**Association Between Tissue HER2 Status (IHC/FISH) and Serum HER2 ECD Levels:**
The bivariate distributions of patients with tissue HER2 status and baseline serum HER2 ECD levels are shown in Table 4. High serum HER2 ECD levels were observed in 40% (8 out of 20) of patients with tissue HER2 positivity and in only 1.67% (1 out of 60) of the patients with tissue HER2 negativity. The P< 0.0001 indicated an association between high HER2 ECD levels and tissue HER2 status (Figure 1).

**Tab. 3. Surgical and cancer treatment**

|                      | Breast cancer patients (N=80) |
|----------------------|-------------------------------|
|                      | N    | %     |
| Radiotherapy         |      |       |
| No                   | 40   | (50%) |
| RT                   | 40   | (50%) |
| Chemotherapy         |      |       |
| No                   | 5    | (6.2%)|
| FAC                  | 51   | (63.8%)|
| FAC-Tax              | 21   | (26.2%)|
| CMF                  | 1    | (1.2%)|
| FAC-Xeloda           | 1    | (1.2%)|
| Tax Gem              | 1    | (1.2%)|
| Hormonal             |      |       |
| No                   | 37   | (46.2%)|
| TAM                  | 33   | (41.2%)|
| AI                   | 8    | (10.0%)|
| TAM-AI               | 2    | (2.5%)|
| Surgery              |      |       |
| Not Done             | 11   | (13.8%)|
| MRM                  | 67   | (83.8%)|
| BCS                  | 2    | (2.5%)|

RT: Radiotherapy; FAC: 5-fluorouracil Adriamycin cyclophosphamide; Tax: taxotere; CMF: cyclophosphamide methotrexate 5-fluorouracil; TAM: tamoxifen; AI: aromatase inhibitor; BCS: breast conservative surgery; MRM: modified radical mastectomy.

**Tab. 4. Association between tissue HER2 status and serum HER2 ECD levels**

| Serum HER2 ECD | Tissue HER2 positive | Tissue HER2 negative | Total | P value     |
|----------------|----------------------|----------------------|-------|-------------|
| High ≥15 ng/mL| 8                    | 1                    | 9     | p< 0.0001*  |
| Low <15 ng/mL | 12                   | 59                   | 71    |             |

*significant at p<0.05; * IHC 3+, IHC 2+ and FISH amplified; IHC: immunohistochemistry; FISH: fluorescence in situ hybridization; ECD: extracellular domain.
**Relationship between Serum HER2 ECD Levels and Clinico-Pathological Variables:**

High HER2 ECD levels were significantly associated with metastasis (P = 0.0024) (Figure 2), negativity of ER (P = 0.0075) (Figure 3), and negativity of PgR (P = 0.0239) (Figure 4). No statistical relationship was found between HER2 ECD levels and the other variables, such as age, tumor size, and lymph node status (Table 5).

**Tab. 5.** Relationship between serum HER2 ECD levels and clinico-pathological variables.

| Characteristics                      | HER2 ECD <15 ng/mL | HER2 ECD ≥15 ng/mL | P value |
|--------------------------------------|--------------------|--------------------|---------|
| Age (year-old)                       |                    |                    |         |
| ≤ 50                                 | 38 (92.7%)         | 3 (7.3%)           | 0.306   |
| > 50                                 | 33 (84.6%)         | 6 (15.4%)          |         |
| Metastasis                           |                    |                    |         |
| Absent                               | 39 (100%)          | 0 (0%)             | 0.0024* |
| Present                              | 32 (78.1%)         | 9 (21.9%)          |         |
| Lymph node status                    |                    |                    |         |
| Negative                             | 15 (100%)          | 0 (0%)             | 0.329   |
| Positive                             | 49 (89.1%)         | 6 (10.9%)          |         |
| Tumor size                           |                    |                    |         |
| Tumor size ≤3                        | 25 (86.2%)         | 4 (13.8%)          | 0.716   |
| Tumor size >3                        | 46 (90.2%)         | 5 (9.8%)           |         |
| Receptor status (cut-off ≥ 10%)      |                    |                    |         |
| ER status                            |                    |                    |         |
| ER negative                          | 21 (75%)           | 7 (25%)            | 0.0075* |
| ER positive                          | 50 (96.2%)         | 2 (3.8%)           |         |
| PgR status                           |                    |                    |         |
| PgR negative                         | 24 (77.4%)         | 7 (22.6%)          | 0.0239* |
| PgR positive                         | 47 (95.9%)         | 2 (4.1%)           |         |

* significant at p<0.05; ER: estrogen receptor; PgR: progesterone receptor.

**Fig. 2.** Association between metastasis and serum HER2 ECD levels.
Determining the HER2/neu status is an integral part of the diagnostic work-up for breast cancer patients. The precise status of HER2 is clinically important because it directs the course of therapeutic treatments for breast cancer patients. The ECD of HER2 can be cleaved from the surface of breast cancer cells by MMPs and released into the serum, where it is detectable using an ELISA [13]. One original goal of serum HER2 ECD is to determine if this type of assay can be used to match the established FISH/IHC tests for HER2 status [6]. Serum HER2 could be used with tissue HER2 as a guide to trastuzumab therapy. The currently approved cutoff for an elevated serum HER2 is greater than 15 ng/mL, which results in a positive test in approximately 5% of healthy controls [14]. We also defined 15 ng/mL the upper limit of normal.

According to our study, an increased serum HER2 level was detected in approximately 11.3% of patients. This rate was close to the mean value of the worldwide studies published between 1992 and 2007 [15]. As shown in Table 4, the (P < 0.0001) indicated an association between high HER2 ECD levels and tissue HER2 status which agreed with Ludovini et al [16] and Tsai et al [17] (Figure 1). However, one of 60 patients was HER2 negative by IHC/FISH but positive by serum HER2 ECD. This patient was a locally advanced and metastatic patient, so this discrepancy may be related to the high tumor burden which is one of the factors associated with high serum HER2 ECD [16].
In our study, elevated levels of HER2 ECD were associated with the absence of ER (P=0.0075) and PgR (P=0.0239) (Table 5, Figures 3, 4). This result is in accordance with studies by (Ludovini et al [16], Tsai et al [17], Ratnatunga et al [18], and Ayadi et al [19]) who demonstrated an inverse association between hormone receptor expression and Her2 overexpression. Furthermore, a recent study has shown that HER family signaling through phosphatidylinositol 3-kinases (PI3-kinase) and serine/threonine-specific protein kinase (AKT) could decrease PR expression [20].

Elevated levels of HER2 ECD were associated with metastasis (P value= 0.0024) (Table 5, Figure 2) but no significant correlation between tissue HER2 status and metastasis was found (Table 6). Our results indicate that the serum level of HER2 ECD is important and has additional value in metastasis than in traditional IHC/FISH methods.

**Tab. 6.** Association between tissue HER2 status and metastasis.

| Tissue HER2 positive | Tissue HER2 negative | Total | P value |
|----------------------|----------------------|-------|---------|
| Metastasis           |                      |       |         |
| Absent               | 9                    | 30    | 39      | 0.798   |
| Present              | 11                   | 30    | 41      |         |
| Total                | 20                   | 60    |         |         |

*IHC 3+, IHC 2+ and FISH amplified; IHC: immunohistochemistry; FISH: fluorescence in situ hybridization; ECD: extracellular domain.*

Serum HER2/neu results were correlated with serum CA 15-3 concentrations as continuous variables. There was a weak but significant correlation between the two markers, with a correlation coefficient of 0.36 (P = 0.005) (Figure 5). Similar results were confirmed by other studies like Molina et al [21] and Ali et al [22]. Of the 9 patients with increased serum HER2/neu, 5 (55.6%) also had increased CA 15-3 (more than 38.6 U/ml). Conversely, 14 of 71 (19.7%) of the patients who did not have increased serum HER2/neu had increased serum CA 15-3.

**Fig. 5.** Significant positive correlation between HER2 ECD (ng/mL) and serum CA 15-3 (U/mL) concentration (r= 0.36, p= 0.005).
The serum levels of other studied parameters are summarized in Table 7.

Tab. 7. Serum concentration of CA 15-3, MMP-9, nitric oxide, and total antioxidant capacity in breast cancer patients as compared to the control group (mean ± SD).

|                     | Control group (N=10) | Breast cancer patients (N=80) | P value |
|---------------------|----------------------|------------------------------|---------|
| CA 15-3 (U/mL)      | 4.92 ± 2.77          | 48.69 ± 57.94*               | <.0001  |
| MMP-9 (ng/mL)       | 305.86 ± 116.18      | 477.1 ± 243.08*              | 0.0013  |
| Nitric oxide (μmol/L)| 293.9 ± 54.64       | 440.8 ± 219.34*              | <0.0001 |
| TAC (mM/L)          | 1.29 ± 0.41          | 0.943 ± 0.39*                | 0.01    |

N: number of patients; * Significant difference from control group at p < (0.05).

CA 15-3 is the most widely used serum tumor marker for breast cancer. In the present study, serum CA 15-3 concentration was elevated significantly in breast cancer patients when compared to the healthy control group (P<0.0001) (Table 7), as reported by Atoum et al [23]. This result is expected because CA 15-3 was considered the most useful tumor marker for monitoring breast cancer patients.

MMP-9 has a causative role in cancer invasion and metastasis, and the development of MMP inhibitors as antimetastatic therapy has started some years ago [24]. As shown in Table 7, we observed significantly higher serum MMP-9 levels in the cancer patients when compared to the control (p= 0.0013). This result agreed with La Rocca et al [25] and Patel et al [26]. Moreover, the serum MMP-9 level was significantly higher in metastatic patients than non-metastatic patients (p= 0.028) (Table 8). This result agreed with Patel et al [26]. That indicated the important role of MMP-9 in the metastasis and invasion of breast cancer. Type IV collagen is abundant in basement membranes separating the epithelial cells from the underlying stroma. Increased expression and activity of MMP-9 in tumors leads to the degradation of basement membranes, an essential step in tumor invasion [27]. As shown in Table 8, no correlation was found between serum MMP-9 and other clinico-pathological parameters considered which agreed with Daniele et al [28].

![Graph showing significant negative correlation between serum MMP-9 concentration (ng/mL) and age (years) (r = −0.329, p = 0.003).](image-url)
We found a negative correlation between serum MMP-9 and age (Figure 6).

**Tab. 8.** Correlation between serum levels of study parameters and clinico-pathological characteristics of breast carcinoma (Mean ± SD).

| Characteristics | MMP9 (ng/mL) | NO (umol/L) | TAC (mM/L) |
|-----------------|-------------|-------------|------------|
| ER              |             |             |            |
| ER negative     | 448.9 ± 242.5 | 447.7 ± 203.3 | 0.99 ± 0.4 |
| ER positive     | 492.3 ± 244.4 | 437.1 ± 229.3 | 0.92 ± 0.4 |
| PR              |             |             |            |
| PR negative     | 410.7 ± 237.8 | 453.7 ± 197.0 | 1.0 ± 0.4  |
| PR positive     | 519.1 ± 239.3 | 432.7 ± 234.0 | 0.9 ± 0.4  |
| Her2            |             |             |            |
| Her2 negative   | 462.0 ± 246.0 | 453.2 ± 232.1 | 0.9 ± 0.4  |
| Her2 positive   | 522.4 ± 234.2 | 403.7 ± 175.7 | 1.0 ± 0.3  |
| Tumor size      |             |             |            |
| T1-T2           | 496.7 ± 220.7 | 438.1 ± 195.0 | 0.9 ± 0.3  |
| T3-T4           | 447.7 ± 274.3 | 444.8 ± 254.8 | 1.0 ± 0.5  |
| Tumor grade     |             |             |            |
| GII             | 483.7 ± 248.3 | 428.2 ± 207.5 | 0.97 ± 0.4 |
| GIII            | 439.7 ± 216.8 | 512.3 ± 276.9 | 0.79 ± 0.3 |
| Lymph node stage|             |             |            |
| Negative        | 411.1 ± 235.4 | 480.7 ± 220.8 | 1 ± 0.3    |
| positive        | 468 ± 236.8  | 421.2 ± 218.8 | 0.93 ± 0.4 |
| Metastasis      |             |             |            |
| Absent          | 416.3* ± 202.3 | 427.6 ± 202.5 | 0.94 ± 0.4 |
| Present         | 534.9* ± 266.0 | 453.4 ± 236.0 | 0.95 ± 0.4 |

* *significant at p<0.05.

We found no significant difference between HER2 ECD-positive (HER2 ECD ≥ 15 ng/mL) and -negative patients (HER2 ECD < 15 ng/mL) in terms of their serum MMP-9 (Table 9). This result agreed with Tsai et al [17]. This indicated that MMP-9 has no role in HER2 shedding, and suggested that another type of protease might be responsible for high serum HER2 ECD levels.

**Tab. 9.** Relationship between Serum levels of MMP-9 and HER2 ECD (Mean ± SD).

| HER2 ECD | MMP-9 conc (ng/mL) | P value |
|----------|---------------------|---------|
| <15ng/mL | 462.9 ± 238.4       | 0.14    |
| ≥15ng/mL | 589.3 ± 265.4       |         |

The role of NOS in tumor biology has not been defined clearly. It is said to have both tumoricidal as well as tumor-promoting effects which depend on its timing, location, and concentration [10]. In our study, breast cancer patients showed significant increases in serum NO levels when compared with control subjects (P<0.0001) (Table 7). However, there was no significant difference between metastatic and non-metastatic patients which
agreed with Günel et al [29] and Konukoglu et al [30] (Table 8). These elevated NO levels might be a result of increased NOS II activity, which was stimulated by a host defense system against tumor growth. NO and NO-derived reactive nitrogen species induce oxidative and nitrosative stress which results in DNA damage (such as nitrosative deamination of nucleic acid bases, transition, and/or transversion of nucleic acids, alkylation, and DNA strand breakage) and the inhibition of DNA repair enzymes (such as alkyltransferase and DNA ligase) through direct or indirect mechanisms. The induction of mutations in cancer-related genes or post-translational modifications of proteins by nitration, nitrosation, phosphorylation, acetylation, or polyADP-ribosylation are some key events that can increase cancer risk [31]. No correlation was found between serum NO and the clinico-pathological parameters considered (Table 8).

One mechanism by which some physiological, physical, lifestyle, and nutritional factors may help to prevent cancer is through the modulation of oxidative stress status [32]. We observed significantly lower serum total antioxidant capacity (p= 0.01) levels in the cancer patients when compared to the control (Table 7). This result agreed with Sener et al [12]. No correlation was found between serum TAC and the clinico-pathological parameters considered (Table 8). In addition to the parameters which are being used for cancer prevention, diagnosis, and treatment, TAC can also be used. Decreasing of TAC may lead to breast cancer, so the antioxidants play an important role in the protection from breast cancer.

Conclusion

Serum HER2 reflects the tissue HER2 status of breast cancer, so the determination of serum HER2 is helpful in the assessment of the HER2 status, but in addition a high level may reflect metastatic disease. Also, serum MMP-9 can be useful for denoting the development of metastasis in breast cancer patients. Follow-up is needed to evaluate the value of serum HER2 and MMP-9 as prognostic markers.

Experimental

Patients

Eighty female patients with breast cancer were recruited from the Oncology Center, Mansoura University, Mansoura, Egypt, diagnosed in the period from 2004 to 2012. Their ages ranged between 26–67 years with a mean ± SD of 49.58± 9. The study was approved by the local institutional ethical committee and patients’ consents were obtained according to the regulations of the Egyptian Ministry of Health. All cases involved in this study were clinically, radiologically, and pathologically examined in the Oncology Center, Mansoura University. Tumor staging followed the tumor–node–metastasis (TNM) American Joint Committee on Cancer classification [33]. Estrogen receptors (ERs), progesterone receptors (PgRs), and HER2 status were assessed at the time of surgery on formalin-fixed paraffin-embedded tissue blocks of the primary tumor in the Oncology Center. Recorded clinical and pathological features for each patient included age, menopausal status, histology, grade, ER and PgR status, stage, surgical treatment, and medical adjuvant therapy.
Patients with other types of malignancy, advanced organ failure, active infection, and advanced medical co-morbidity were excluded from the study.

**Control Group**

A negative control group comprised 10 healthy females with no apparent evidence of active disease or a medical disorder. Their ages ranged between 39–53 years with a mean ± SD of 46.00 ± 4.47.

**Blood Sampling**

Fasting blood samples were collected from all patients and control groups. This blood was left to clot for 20–30 min at room temperature, followed by centrifugation at 1500 g for 10 min. The serum was then transferred to a polypropylene tube and stored at −80°C until use.

**Measurement of Serum HER2 ECD**

The HER2 ECD levels were measured using ELISA (eBioscience human sHER-2 platinum ELISA kit, San Diego, California, USA.), following the manufacturer’s recommended protocol. The concentration of HER2 ECD in the samples was determined by interpolation of the sample absorbance from the standard curve. The minimum detectable was 0.06 ng/mL. The calculated overall intra-assay coefficient of variation was 1.9% and the calculated overall inter-assay coefficient of variation was 5.8%. The upper limit of normal was defined as 15 ng/mL, as previously reported [34].

**Serum MMP-9 Assays**

Serum MMP-9 (92 kDa Pro- and 82 kDa active forms) was determined using ELISA (R&D Systems, Catalog # PDMP900 ELISA kit, Inc., U.S.A.) as per the manufacturer's protocol. The minimum detectable level of MMP-9 is typically less than 0.156 ng/mL.

**Serum Nitric Oxide Assays**

NO concentrations were determined using (R&D Systems, Catalog # KGE001, Inc., U.S.A.). This kit determines NO concentrations based on the enzymatic conversion of nitrate to nitrite by nitrate reductase. The reaction is followed by colorimetric detection of nitrite as an azo dye product of the Griess Reaction.

**Serum Total Antioxidant Capacity Assays**

The serum TAC was determined according to the method of Koracevic et al [35] by using a commercially available colorimetric kit (from Biodiagnostic, Giza, Egypt).

**Serum CA 15-3 Assays**

Serum CA 15-3 was determined using an ELISA kit (MyBioSource, San Diego, California, USA).

**Detection of Metastasis**

Diagnosis of metastasis was dependent on clinical examination including symptomatology, together with radiology including a plan X-ray, ultrasonography, CT, bone scan, and tumor marker (CA 15-3).
Tissue ER and PgR Analysis

ER and PgR status were evaluated by IHC on formalin-fixed, paraffin-embedded tissue sections using monoclonal antibodies and a standard methodology. Slides were scanned microscopically using the Allred score on a scale of 0 to 8. A score greater than 2 (corresponding to as few as 1% to 10% weakly positive cells) was used to define ER and PgR positivity.

Tissue HER2 Analysis

IHC staining of specimens was carried out on formalin-fixed, paraffin-embedded breast cancer tissues using the mAb CB11 which targets the intracellular domain of the HER2/neu protein (BioGenex, San Ramon, CA). According to the Hercep Test criteria, an immunoreaction was scored as: 3+ if >10% of tumor cells showed strong and complete membrane staining, 2+ if membrane positivity was moderate and complete in >10% cells, 1+ if membrane positivity was weak and incomplete in >10% cells, and 0 if membrane staining was absent or present in <10% cells. Tumors scored as 3+ were considered HER2-positive while tumors scored as 0/1+ were designated as HER2-negative. In 2+ tumors evaluated by IHC, FISH analysis was carried out, using the Abbott-Vysis Path Vysion HER2 DNA Probe Kit (Abbott Laboratories, Abbott Park, IL), following the manufacturer’s recommended protocol. The results were reported as the ratio between the average copy number of the HER2/neu gene and that of the chromosome 17 centromere, analyzing 60 neoplastic nuclei. Specimens with a signal ratio of <2.0 were considered as nonamplified and 2.0 or greater as amplified.

Statistical Analysis

For descriptive statistics, the frequency and percentage were calculated for qualitative variables, the mean values ± standard deviation (SD) were used for quantitative variables. For comparison between the two groups Student’s t-test was used. For correlation, Pearson correlation was used. Statistical computations were done on a personal computer using the computer software SPSS version 18 (Chicago, IL, USA) and GraphPad Prism 5. The Fisher’s exact test was used to assess the association among the clinical–pathological features and the levels of HER2 ECD. All p-values were two-sided and a p-value of less than 0.05 was considered to indicate a statistically significant difference.

Acknowledgement

The authors are extremely grateful to Dr. Sameh Shamaa professor of medical oncology at Mansoura Oncology Center for his continuous help.

Authors’ Statements

Competing Interests

The authors declare no conflict of interest.

Informed Consent, Ethical Approvals

The institutional and national ethical guides for experiments on human subjects were followed and informed consent was obtained. See ‘Experimental’ for details.
References

[1] Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O'Shaughnessy JA, Shen ZZ, Albain KS. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005; 6: 391–401. http://dx.doi.org/10.3816/CBC.2005.n.043

[2] Denewer A, Farouk O, Mostafa W, Elshamy K. Social support and hope among egyptian women with breast cancer after mastectomy. Breast Cancer (Auckl). 2011; 5: 93–103. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117623/

[3] Roy V, Perez EA. Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist. 2009; 14: 1061–1069. http://dx.doi.org/10.1634/theoncologist.2009-0142

[4] Tsé C, Gauchez AS, Jacot W, Lamy PJ. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev. 2012; 38:133–142. http://dx.doi.org/10.1016/j.ctrv.2011.03.008

[5] Allison M. The HER2 testing conundrum. Nat Biotechnol. 2010; 28: 117–119. http://dx.doi.org/10.1038/nbt0210-117

[6] Lam L, McAndrew N, Yee M, Fu T, Tchou JC, Zhang H. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012; 1826: 199–208. http://www.ncbi.nlm.nih.gov/pubmed/22521738

[7] Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci. 2006; 11: 479–491. http://dx.doi.org/10.2741/1811

[8] Sanderson MP, Dempsey PJ, Dunbar AJ. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors. 2006; 24: 121–136. http://dx.doi.org/10.1080/08977190600634373

[9] Stankovic S, Konjevic G, Gopcevic K, Jovic V, Inic M, Jurisic V. Activity of MMP-2 and MMP-9 in sera of breast cancer patients. Pathol Res Pract. 2010; 206: 241–247. http://dx.doi.org/10.1016/j.prp.2009.12.003

[10] Choudhari SK, Chaudhary M, Bagde S, Gadbai AR, Joshi V. Nitric oxide and cancer: a review. World J Surg Oncol. 2013; 11: 118. http://dx.doi.org/10.1186/1477-7819-11-118

[11] Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer. 2006; 6: 521–534. http://dx.doi.org/10.1038/nrc1910

[12] Sener DE, Gönenc A, Akinci M, Torun M. Lipid peroxidation and total antioxidant status in patients with breast cancer. Cell Biochem Funct. 2007; 25: 377–382. http://dx.doi.org/10.1002/cbf.1308
[13] Park NK, Woo HD, Sohn DM, Kim SY, Lim CW, Choi TY, Kim JJ, Lee MH. The correlation of serum HER-2/neu and CA15-3 in patients with metastatic breast cancer. J Breast Cancer. 2008; 11: 18–24. http://dx.doi.org/10.4049/jbc.2008.11.1.18

[14] Müller V, Witzel I, Pantel K, Krenkel S, Lück HJ, Neumann R, Keller T, Dittmer J, Jänicke F, Thomssen C. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res. 2006; 26: 1479–1487. http://www.ncbi.nlm.nih.gov/pubmed/16619561

[15] Leary AF, Hanna WM, van de Vijver MJ, Penault-Llorca F, Rüschhoff J, Osamura RY, Bilous M, Dowsett M. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol. 2009; 27: 1694–1705. http://dx.doi.org/10.1200/JCO.2008.17.3989

[16] Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C, Rulli A, Crinò L. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol. 2008; 19: 883–890. http://dx.doi.org/10.1093/annonc/mdm585

[17] Tsai HP, Chen SC, Chien HT, Jan YY, Chao TC, Chen MF, Hsieh LL. Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer. World J Surg Oncol. 2012; 10:42. http://dx.doi.org/10.1186/1477-7819-10-42

[18] Ratnatunga N, Liyanapathirana LV. Hormone receptor expression and Her/2neu amplification in breast carcinoma in a cohort of Sri Lankans. Ceylon Med J. 2007; 52: 133–136. http://www.ncbi.nlm.nih.gov/pubmed/18286776

[19] Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, Boudawara T. Correlation of HER-2 over-expression with clinicopathological parameters in Tunisian breast carcinoma. World J Surg Oncol. 2008; 6: 112. http://dx.doi.org/10.1186/1477-7819-6-112

[20] Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, Koga T, Morita M, Kakeji Y, Maehara Y. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat. 2007; 101: 249–257. http://dx.doi.org/10.1007/s10549-006-9295-8

[21] Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Munoz M, Farrus B, Ballesta AM. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res. 2003; 23: 1043–1050. http://www.ncbi.nlm.nih.gov/pubmed/12820345

[22] Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, Carney W, Allard JW, Lipton A. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem. 2002; 48: 1314–1320. http://www.ncbi.nlm.nih.gov/pubmed/12142389
[23] Atoum M, Nimer N, Abdeldayem S, Nasr H. Relationships among serum CA15-3 tumor marker, TNM staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions. Asian Pac J Cancer Prev. 2012; 13: 857–860. http://dx.doi.org/10.7314/APJCP.2012.13.3.857

[24] Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des. 2007; 13: 333–346. http://dx.doi.org/10.2174/138161207779313551

[25] La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer. 2004; 90: 1414–1421. http://dx.doi.org/10.1038/sj.bjc.6601725

[26] Patel S, Sumitra G, Koner BC, Saxena A. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clin Biochem. 2011; 44: 869–872. http://dx.doi.org/10.1016/j.clinbiochem.2011.04.019

[27] Köhrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer. 2009; 9: 188. http://dx.doi.org/10.1186/1471-2407-9-188

[28] Daniele A, Zito AF, Giannelli G, Divella R, Asselti M, Mazzocca A, Paradiso A, Quaranta M. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res. 2010; 30: 3521–3527. http://www.ncbi.nlm.nih.gov/pubmed/20944132

[29] Günel N, Coşkun U, Sancak B, Günel U, Hasdemir O, Bozkurt S. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer. 2002; 95: 663–667. http://dx.doi.org/10.1002/cncr.10705

[30] Konukoglu D, Turhan MS, Celik V, Turna H. Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients. Indian J Med Res. 2007; 125: 747–751. http://www.ncbi.nlm.nih.gov/pubmed/17704550

[31] Muntané J, la Mata MD. Nitric oxide and cancer. World J Hepatol. 2010; 2: 337–344. http://dx.doi.org/10.4254/wjh.v2.i9.337

[32] Vieira FG, Di Pietro PF, Boaventura BC, Ambrosi C, Rockenbach G, Fausto MA, Crippa CG, Da Silva EL. Factors associated with oxidative stress in women with breast cancer. Nutr Hosp. 2011; 26: 528–536. http://www.ncbi.nlm.nih.gov/pubmed/21892571

[33] Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002; 20: 3628–3636. http://dx.doi.org/10.1200/JCO.2002.02.026
[34] Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, Hudis C. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol. 2005; 16: 234–239. http://dx.doi.org/10.1093/annoncmdi059

[35] Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V. Method for the measurement of antioxidant activity in human fluids. J Clin Pathol. 2001; 54: 356–361. http://dx.doi.org/10.1136/jcp.54.5.356